Arvest Investments Inc. Has $872,000 Stock Position in Pfizer Inc. $PFE

Key Points

• Arvest Investments Inc. has decreased its stake in Pfizer Inc. by 26.2%, selling 12,776 shares during the second quarter, bringing its total holdings to $872,000.
• Pfizer reported earnings of $0.78 per share, exceeding analysts' expectations of $0.58 for the quarter, with revenue of $14.65 billion.
• Pfizer announced a quarterly dividend of $0.43, with a yield of 7.2% and a current dividend payout ratio of 91.49%.

Arvest Investments Inc. reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 26.2% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,989 shares of the biopharmaceutical company's stock after selling 12,776 shares during the quarter. Arvest Investments Inc.'s holdings in Pfizer were worth $872,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in PFE. Pacer Advisors Inc. raised its stake in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi increased its holdings in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares in the last quarter. Nuveen LLC bought a new stake in Pfizer during the 1st quarter worth approximately $389,861,000. Starboard Value LP bought a new stake in Pfizer during the 4th quarter worth approximately $407,730,000. Finally, Goldman Sachs Group Inc. increased its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after purchasing an additional 9,041,990 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $23.91 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business has a fifty day simple moving average of $24.79 and a two-hundred day simple moving average of $24.28. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The company has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a P/E/G ratio of 0.88 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period last year, the business posted $0.60 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of analysts have commented on the company. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Finally, Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.